Search
for
Sort by
Research 871–900 of 1000+
- Phase II trial of paclitaxel poliglumex (CT-2103) in pre- and post-menopausal women on hormonal replacement therapy (HRT) with non-small cell lung cancer (NSCLC).
- Continuous MEK inhibition by AZD6244 (ARRY-142886) results in exhaustion of the cutaneous keratinocytic stem cell pool and resembles senescence driven skin aging
- Nearly complete hair re-pigmentation in an older patient treated with hydroxyurea for essential thrombocytosis
- The patient outcomes with EGFR-mutated advanced non-small-cell lung cancer receiving aumolertinib as first-line treatment.
- Scalp hypothermia for the prevention of chemotherapy-induced alopecia in breast cancer
- Challenges associated with the identification of germline variants on myeloid malignancy genomic profiling—a Singaporean experience
- Oral minoxidil for the treatment of late alopecia in cancer survivors.
- Patient-Reported Outcomes From Phase III Neoadjuvant Systemic Trial Comparing Neoadjuvant Chemotherapy With Neoadjuvant Endocrine Therapy in Pre-Menopausal Patients With Estrogen Receptor-Positive and HER2-Negative, Lymph Node-Positive Breast Cancer
- ES01.01 Chemotherapy is Strictly Additive to Immunotherapy
- Alopecia/hair loss in all patients treated with trastuzumab and paclitaxel: myth or reality?
- A phase I safety study of topical calcitriol (BPM 31543) for the prevention of chemotherapy-induced alopecia (CIA).
- Epidermal cyst of temporal bone as a delayed complication of myringoplasty
- Three Cases of Hemodialysis Patients with Advanced Gastric Cancer Treated with Paclitaxel and Nab Paclitaxel
- Prospective Study on the Short-Term Adverse Effects From Gamma Knife Radiosurgery
- Phase I-II trial of weekly bicalutamide in men with high PSA and negative biopsy
- Lysocellin, a metabolite of the novel drug ‘alopestatin’, induces G1 arrest and prevents cytotoxicity induced by etoposide
- Scalp Segmentation and Permanent Alopecia Prediction in Pediatric Craniospinal Irradiation: The PAST and HOPE Projects
- Patient experience with later line chemotherapy in four tumor types.
- Long-term hair loss associated with brentuximab vedotin–containing chemotherapy and its psychosocial impact: A retrospective observational study conducted at the Royal Marsden Hospital.
- Hair relaxer use and breast cancer risk by tumor molecular subtypes.
- Skin toxicity induced by chemotherapy or molecular targeted therapy combined with immune checkpoint inhibitors in Asian patients: A literature review by the Japanese Pharmacist-led Oncodermatology Study Team
- Association of prior 5-α-reductase inhibitor exposure with ICI benefit in metastatic RCC: Multicentre cohort with single-cell immune profiling.
- Search for New antineoplastic agents based on structural modifications of steroidal 5α-reductase, 17β-hydroxysteroid dehydrogenase, and 17α-hydroxylase/17,20-lyase inhibitors
- Cancer-Related Alopecia Risk and Treatment
- Pigmentary-Hair-Follicle Unit Under Innovative Pathologic Investigation - Is There a Potential to Improve Outcome of Sensor-Controlled Scalp-Cooling?
- A Review Of Various Methods Of Treating Skin Cancer Based On The Use Of Bio-Based Materials
- Effects of scalp lotion containing alpha lipoic acid derivatives for chemotherapy-induced alopecia in patients with gastrointestinal cancer: A prospective cohort study
- Evaluating changes in the breast cancer-related quality of life of young women with breast cancer: long-term results from a multicenter prospective cohort
- Acute severe hypokalemia caused by treatment of tongue squamous cell carcinoma with docetaxel and cisplatin: A case report
- Chemical hair relaxer use and its potential effect on incidence of endometrial cancer in Black women.